Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

References

• KamangarFDoresGMAndersonWFPatterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the worldJ Clin Oncol2006242137215016682732
   PubMed Web of Science ®Google Scholar
• GoldstrawPCrowleyJChanskyKThe IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJ Thorac Oncol2007270671417762336
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet20053661527153716257339
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Eng J Med200635525422550
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet20093731525153119410716
   PubMed Web of Science ®Google Scholar
• CiardielloFBiancoRDamianoVAntiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cellsClin Cancer Res200063739374710999768
   PubMed Web of Science ®Google Scholar
• GuySPAshtonSHughesGGefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft modelsClin Cancer Res200396142s (abstract B13).
   Web of Science ®Google Scholar
• TonraJRDeeviDSCorcoranESynergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapyClin Cancer Res2006122197220716609035
   PubMed Web of Science ®Google Scholar
• RobinsonDRWuYMLinSFThe protein tyrosine kinase family of the human genomeOncogene2000195548555711114734
   PubMed Web of Science ®Google Scholar
• GilleHKowalskiJLiBAnalysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutantsJ Biol Chem20012763222323011058584
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med2003966967612778165
   PubMed Web of Science ®Google Scholar
• Munoz-ChapuliRQuesadaARAngel MedinaMAngiogenesis and signal transduction in endothelial cellsCell Mol Life Sci2004612224224315338053
   PubMed Web of Science ®Google Scholar
• JainRKNormalization of tumor vasculature: An emerging concept in antiangiogenic therapyScience2005307586215637262
   PubMed Web of Science ®Google Scholar
• OlayioyeMANeveRMLaneHAHynesNEThe ErbB signaling network: receptor heterodimerization in development and cancerEmbo J2000193159316710880430
   PubMed Web of Science ®Google Scholar
• IsobeTHerbstRSOnnACurrent management of advanced non-small cell lung cancer: targeted therapySemin Oncol20053231532815988686
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
   PubMed Web of Science ®Google Scholar
• Paz-AresLSanchezJMGarcía-VelascoAA prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I2006247020
   Web of Science ®Google Scholar
• MokTSWuY-LThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• PhamDKrisMGRielyGJUse of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomasJ Clin Oncol200624170016505411
   PubMed Web of Science ®Google Scholar
• CiardielloFCaputoRDamianoVAntitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseClin Cancer Res200391546155612684431
   PubMed Web of Science ®Google Scholar
• De LucaACarotenutoARachiglioAThe role of the EGFR signaling in tumor microenvironmentJ Cell Physiol200821455956717894407
   PubMed Web of Science ®Google Scholar
• HirataAOgawaSKometaniTZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinaseCancer Res2002622554256011980649
   PubMed Web of Science ®Google Scholar
• PetitAMRakJHungMCNeutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumorsAm J Pathol1997151152315309403702
   PubMed Web of Science ®Google Scholar
• BiancoRGarofaloSRosaRInhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugsBr J Cancer20089892393018319715
   PubMed Web of Science ®Google Scholar
• Viloria-PetitAMKerbelRSAcquired resistance to EGFR inhibitors: Mechanisms and prevention strategiesInt J Radiat Oncol Biol Phys20045891492614967451
   PubMed Web of Science ®Google Scholar
• HerbstRSO’NeillVJFehrenbacherLPhase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerJ Clin Oncol2007254743475017909199
   PubMed Web of Science ®Google Scholar
• HainsworthRHA phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA)Thoracic Oncol20083S302
   Google Scholar
• MillerVAO’ConnorPSohCKabbinavarFA randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)J Clin Onco l20092718s (abstract LBA8002).
   Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res2002624645465512183421
   PubMed Web of Science ®Google Scholar
• AraoTFukumotoHTakedaMSmall in-frame deletion in the epidermal growth factor receptor as a target for ZD6474Cancer Res2004649101910415604279
   PubMed Web of Science ®Google Scholar
• TaguchiFKohYKoizumiFAnticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)-sensitive and resistant xenograft modelsCancer Sci20049598498915596048
   PubMed Web of Science ®Google Scholar
• CiardielloFBiancoRCaputoRAntitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapyClin Cancer Res20041078479314760102
   PubMed Web of Science ®Google Scholar
• WuWOnnAIsobeTTargeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockadeMol Cancer Ther2007647148317308046
   PubMed Web of Science ®Google Scholar
• HoldenSNEckhardtSGBasserRClinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnn Oncol2005161391139715905307
   PubMed Web of Science ®Google Scholar
• TamuraTMinamiHYamadaYA phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumorsJ Thorac Oncol200611002100917409986
   PubMed Web of Science ®Google Scholar
• De BoerRHumbletYWolfJAn open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancerAnn Oncol20092048649119088171
   PubMed Web of Science ®Google Scholar
• KiuraKNakagawaKShinkaiTA randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancerJ Thorac Oncol2008338639318379357
   PubMed Web of Science ®Google Scholar
• NataleRBBodkinDGovindanRVandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II studyJ Clin Oncol2009272523252919332730
   PubMed Web of Science ®Google Scholar
• HeymachJVJohnsonBEPragerDRandomized placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancerJ Clin Oncol2007254270427717878479
   PubMed Web of Science ®Google Scholar
• HeymachJVPaz-AresLDe BraudFRandomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJ Clin Oncol2008265407541518936474
   PubMed Web of Science ®Google Scholar
• DaviesAMHoCLaraPNPharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancerClin Lung Cancer2006738538816800963
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol2005235892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol2007251545155217442998
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2J Clin Oncol20042278579414990633
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol20042277778414990632
   PubMed Web of Science ®Google Scholar
• HanrahanEORyanAJMannHBaseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerClin Cancer Res2009153600360919447868
   PubMed Web of Science ®Google Scholar
• HanrahanEOLinHYKimESDistinct patterns of change in plasma cytokine and angiogenic factors and markers of benefit for vandetanib and/or chemotherapy in non-small cell lung cancer patientsJ Clin Oncol20102819320119949019
   PubMed Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAVandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST)J Clin Oncol200927 abstract 8009.
   Web of Science ®Google Scholar
• De BoerRArrietaOGottfriedMVandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL)J Clin Oncol200927409s abstract 8010.
   Google Scholar
• HerbstRSSunYKorfeeSVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advance non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC)J Clin Oncol200927807s abstract CRA8003.
   Web of Science ®Google Scholar
• US National Institutes of HealthZD6474 (ZACTIMA™) Phase III Study in EGFR Failures8102010 Available from: http://clinical-trials.gov/ct2/show/NCT00404924. Accessed Aug 11, 2010.
   Google Scholar
• US National Institutes of HealthZactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine (ZELIG)7132010 Available from: http://clinicaltrials.gov/ct2/show/NCT00753714. Accessed Aug 11, 2010.
   Google Scholar
• US National Institutes of HealthStudy of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer1212009 Available from: http://clinicaltrials.gov/ct2/show/NCT00687297. Accessed Mar 21, 2010.
   Google Scholar
• US National Institutes of HealthPhase II of Zactima Maintenance for Locally Advanced or Metastatic NSCLC Following Platinum-doublet Chemotherapy6282010 Available from: http://clinicaltrials.gov/ct2/show/NCT00777179. Accessed Aug 11, 2010.
   Google Scholar
• US National Institutes of HealthRadiation Therapy (XRT)and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)412010 Available from: http://clinicaltrials.gov/ct2/show/NCT00745732. Accessed Aug 11, 2010.
   Google Scholar
• US National Institutes of HealthInvestigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases1252010 Available from: http://clinicaltrials.gov/ct2/show/NCT00807170. Accessed Mar 21, 2010.
   Google Scholar
• US National Institutes of HealthBATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC2262010 Available from: http://clinicaltrials.gov/ct2/show/NCT00410189. Accessed Mar 21, 2010.
   Google Scholar
• US National Institutes of HealthMalignant Pleural Effusion With ZD6474162010 Available from: http://clinicaltrials.gov/ct2/show/NCT00402896. Accessed Mar 21, 2010.
   Google Scholar
• US National Institutes of HealthPaclitaxel, Carboplatin, and High-Dose Radiation Therapy With or Without Vandetanib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer1072009 Available from: http://clinicaltrials.gov/ct2/show/NCT00975260. Accessed Mar 21, 2010.
   Google Scholar
• US National Institutes of HealthVandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery262009 Available from: http://clinicaltrials.gov/ct2/show/NCT00459121. Accessed Mar 21, 2010.
   Google Scholar
• US National Institutes of HealthPhase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC482009 Available from: http://clinicaltrials.gov/ct2/show/NCT00496275. Accessed Mar 21, 2010.
   Google Scholar